WAM
ACOR

Wealthspire Advisors (Maryland)’s Acorda Therapeutics ACOR Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1
Closed -$2K – 2235
2019
Q1 		$2K Buy
+1
New +$1.8K ﹤0.01% 2240
2018
Q4 		– Sell
-1
Closed -$2K – 2607
2018
Q3 		$2K Hold
1
– – ﹤0.01% 2220
2018
Q2 		$3K Buy
+1
New +$3.06K ﹤0.01% 2078
2018
Q1 		– Hold
0
– – – 2431
2017
Q4 		– Hold
0
– – – 2593
2017
Q3 		– Hold
0
– – – 2521

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ACOR Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Acorda Therapeutics (ACOR) in Q2 2019, closing a stake of 1 share — an estimated $2K sold.

Wealthspire Advisors (Maryland) first reported a position in ACOR in Q2 2018 and held it in 3 quarters. The position peaked at $3K in Q2 2018. 163 funds tracked by Wall St. Rank hold ACOR as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Acorda Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 1 Acorda Therapeutics share in Q2 2019, an estimated $2K.
  • Wealthspire Advisors (Maryland) first reported a position in Acorda Therapeutics in Q2 2018 and held it in 3 quarters.
  • Wealthspire Advisors (Maryland)'s Acorda Therapeutics position peaked at $3K in Q2 2018.
  • 163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.